Terns Pharmaceuticals (NASDAQ:TERN) Insider Sells $49,690.50 in Stock

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) insider Emil Kuriakose sold 942 shares of the stock in a transaction on Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total value of $49,690.50. Following the completion of the transaction, the insider directly owned 105,673 shares in the company, valued at approximately $5,574,250.75. This trade represents a 0.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Emil Kuriakose also recently made the following trade(s):

• On Friday, January 2nd, Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock. The stock was sold at an average price of $38.57, for a total value of $44,548.35.

Terns Pharmaceuticals Stock Performance

TERN opened at $52.72 on Friday. The business’s 50-day simple moving average is $42.96 and its 200 day simple moving average is $30.80. Terns Pharmaceuticals, Inc. has a 52-week low of $1.87 and a 52-week high of $53.19. The firm has a market capitalization of $6.08 billion, a PE ratio of -51.18 and a beta of -0.37.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Thursday, April 2nd. The company reported ($0.24) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.30) by $0.06. On average, research analysts forecast that Terns Pharmaceuticals, Inc. will post -1.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

TERN has been the topic of a number of analyst reports. Oppenheimer increased their price target on Terns Pharmaceuticals from $28.00 to $58.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. Mizuho downgraded Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Friday, March 27th. HC Wainwright reissued a “neutral” rating and set a $53.00 target price (down from $60.00) on shares of Terns Pharmaceuticals in a report on Wednesday, March 25th. Truist Financial cut Terns Pharmaceuticals from a “buy” rating to a “hold” rating and decreased their price target for the stock from $56.00 to $53.00 in a research report on Tuesday, March 31st. Finally, Citizens Jmp cut shares of Terns Pharmaceuticals from a “market outperform” rating to a “hold” rating in a research report on Thursday, March 26th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Terns Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $56.30.

Institutional Investors Weigh In On Terns Pharmaceuticals

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Terns Pharmaceuticals during the 4th quarter valued at approximately $25,000. GAMMA Investing LLC lifted its stake in Terns Pharmaceuticals by 762.4% in the 4th quarter. GAMMA Investing LLC now owns 871 shares of the company’s stock valued at $35,000 after purchasing an additional 770 shares during the last quarter. iA Global Asset Management Inc. bought a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth $43,000. FNY Investment Advisers LLC bought a new stake in shares of Terns Pharmaceuticals during the fourth quarter worth $80,000. Finally, EverSource Wealth Advisors LLC grew its stake in shares of Terns Pharmaceuticals by 61.6% during the fourth quarter. EverSource Wealth Advisors LLC now owns 2,207 shares of the company’s stock worth $89,000 after buying an additional 841 shares during the last quarter. 98.26% of the stock is currently owned by institutional investors.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.